Opportunity, Llc Vivo Oppor... Net Worth

The estimated Net Worth of Opportunity, Llc Vivo Oppor... is at least $407 Millón dollars as of 27 August 2024. Opportunity Oppor owns over 1,025,000 units of Soleno Therapeutics Inc stock worth over $305,658,122 and over the last few years Opportunity sold SLNO stock worth over $100,913,562.

Opportunity Oppor SLNO stock SEC Form 4 insiders trading

Opportunity has made over 2 trades of the Soleno Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Opportunity sold 1,025,000 units of SLNO stock worth $49,210,250 on 27 August 2024.

The largest trade Opportunity's ever made was selling 1,101,242 units of Soleno Therapeutics Inc stock on 29 April 2024 worth over $51,703,312. On average, Opportunity trades about 531,561 units every 30 days since 2023. As of 27 August 2024 Opportunity still owns at least 6,291,851 units of Soleno Therapeutics Inc stock.

You can see the complete history of Opportunity Oppor stock trades at the bottom of the page.

What's Opportunity Oppor's mailing address?

Opportunity's mailing address filed with the SEC is 192 LYTTON AVENUE192 LYTTON AVENUE, , PALO ALTO,PALO ALTO,, CACA, 9430194301.

Insiders trading at Soleno Therapeutics Inc

Over the last 9 years, insiders at Soleno Therapeutics Inc have traded over $134,327,999 worth of Soleno Therapeutics Inc stock and bought 56,592,152 units worth $70,324,676 . The most active insiders traders include Advisors Llcperceptive Life..., Jack W Schuler y Andrew Sinclair. On average, Soleno Therapeutics Inc executives and independent directors trade stock every 29 days with the average trade being worth of $36,911,570. The most recent stock trade was executed by Kristen Yen on 28 August 2024, trading 10,705 units of SLNO stock currently worth $507,738.

What does Soleno Therapeutics Inc do?

soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.

Complete history of Opportunity Oppor stock trades at Soleno Therapeutics Inc

Soleno Therapeutics Inc executives and stock owners

Soleno Therapeutics Inc executives and other stock owners filed with the SEC include:

• Anish Bhatnagar,
  President, Chief Executive Officer, Director
• Dr. Anish Bhatnagar,
  Pres, CEO, COO & Director
• Patricia Hirano,
  Vice President - Regulatory Affairs
• Kristen Yen,
  Vice President - Clinical Operations
• James H. MacKaness,
  Chief Financial Officer
• Ernest Mario,
  Independent Chairman of the Board
• William Harris,
  Independent Director
• Gwen Melincoff,
  Independent Director
• Birgitte Volck,
  Independent Director
• Andrew Sinclair,
  Independent Director
• Dr. Neil M. Cowen M.B.A., Ph.D., MBA,
  Sr. VP of Drug Devel.
• Anthony Wondka,
  Sr. VP & GM
• Dawn Carter Bir,
  
• Jack W Schuler,
  
• Larry N Feinberg,
  10% owner
• Opportunity, Llc Vivo Oppor...,
  
• Jonathan Wolter,
  Chief Financial Officer
• Stephen Kirnon,
  Director
• Mahendra Shah,
  Director
• Rajen Dalal,
  Director
• Edgar Engleman,
  Director
• Ventures V, Llc Vivo,
  10% owner
• Steinar J Engelsen,
  Director
• James Walter Glasheen,
  Director
• Stuart J Collinson,
  Director
• Ventures V, Llc Vivo Ventur...,
  
• Raymond W. Urbanski,
  CHIEF DEVELOPMENT OFFICER
• Management Vii Llctechnolog...,
  
• Mangement Llcbioasia Invest...,
  
• Larry Noracle Partners Lp F...,
  
• Llp Abingworth,
  10% owner
• Ventures V, Llc Vivo Ventur...,
  
• Group Inc.Carlyle Holdings ...,
  
• Meredith Manning,
  Chief Commercial Officer
• Michael F. Huang,
  Sr. VP of Clinical Development
• Matthew Pauls,
  
• Group Inc.Carlyle Holdings ...,
  
• Advisors Llcperceptive Life...,
  
• James H Mackaness,
  CHIEF FINANCIAL OFFICER